Trial Profile

A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Proof of concept; Therapeutic Use
Sponsors BerGenBio

Most Recent Events

30 Apr 2025 Results presented at the 116th Annual Meeting of the American Association for Cancer Research.
06 Nov 2023 According to a BerGenBio media release, data from the study were presented at the 2023 Society of Immunotherapy of Cancer Annual Meeting.
31 Oct 2023 According to a BerGenBio media release, the full poster from this study will be available on BerGenBio's website shortly following presentation on November 4th.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com